Top Markets
#1 MowCat MowCat +48.54%
#2 Bitway Bitway +25.99%
#3 Velvet Velvet +24.18%
#4 aPriori aPriori +19.71%
#5 OVERTAKE OVERTAKE +18.89%
#6 Biconomy Biconomy +16.58%
#7 Derive Derive +14.54%
#8 Zerebro Zerebro +13.25%
#9 Fake World Assets Fake World Assets +11.25%
#10 DODO DODO +11.08%
Coin of the day
MowCat MowCat
Settings
Language
ENGLISH
Currency
USD
Theme
Nicox S.A. Nicox S.A.

Nicox S.A.

COX
Rank in Stocks #34243
Nicox S.A. is an ophthalmology enterprise operating both within France and... Nicox S.A. is an ophthalmology enterprise operating both within France and globally, focused on developing therapies to safeguard vision and enhance overall eye health. Its leading investigational drug, NCX 470, an innovative nitric oxide-donating prostaglandin analog designed to decrease intraocular pressure in individuals with open-angle glaucoma or ocular hypertension, is currently undergoing Phase 3 clinical trials. Furthermore, the company is progressing NCX 4251, a specialized fluticasone formulation, through a Phase 2b clinical trial for the management of acute exacerbations of blepharitis, as well as NCX 1728. Nicox also provides VYZULTA, a latanoprostene bunod ophthalmic solution for treating open-angle glaucoma or ocular hypertension, and ZERVIATE, a cetirizine ophthalmic solution to relieve ocular itching related to allergic conjunctivitis. The company, established in 1996, has its main office situated in Valbonne, France.
Share Price
$0.6379482
Last synced: 2023-05-22
Market Cap
$5.98M
Change (1 day)
-0.44%
Change (1 year)
0.00%
Country
FR
Trade Nicox S.A. (COX)

Category

Healthcare
Revenue for Nicox S.A. (COX)
Revenue in Aug 2026 TTM: 0
According to Nicox S.A. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Nicox S.A. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE